Malignant proliferation of tumor cells induced by gefitinib/osimertinib resistance were due to hypermethylation of the MUC17-specific promoter caused by the UHRF1/DNMT1 complex, which activates the NF-κB signaling pathway. Here, MUC17 is linked to neoplasm.